EDITAS MEDICINE Reports 2nd Quarter FY2023 Earnings Results on August 2 2023

August 11, 2023

🌥️Earnings Overview

On August 2 2023, EDITAS MEDICINE ($NASDAQ:EDIT) reported their financials for the second quarter of FY2023, which ended June 30 2023. Total revenue for the quarter was USD 2.9 million, a decrease of 54.6% compared to the same time last year. Net income was USD -40.3 million, a 24.1% improvement from -53.4 million in the prior year.

Market Price

On Wednesday August 2 2023, EDITAS MEDICINE reported its second quarter earnings results for fiscal year 2023. The company’s stock opened at $8.5 and closed at $9.1, representing a 5.7% increase from its prior closing price of $8.6. This marked a significant jump in the company’s stock price, as investors reacted positively to the news.

Additionally, the company announced a new partnership with pharmaceutical giant Merck for the development of gene therapy treatments. This partnership is set to boost EDITAS MEDICINE’s future prospects and further increase investor interest in the company. Overall, EDITAS MEDICINE’s second quarter earnings results were promising. The company exceeded expectations in terms of revenue, and its new partnership with Merck could open up new opportunities for further growth. This positive outlook appears to have been reflected by the increased value of the company’s stock, which closed at $9.1 on Wednesday. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Editas Medicine. More…

    Total Revenues Net Income Net Margin
    19.32 -205.79 -1065.4%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Editas Medicine. More…

    Operations Investing Financing
    -164.76 97.95 118.22
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Editas Medicine. More…

    Total Assets Total Liabilities Book Value Per Share
    541.95 142.04 4.9
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Editas Medicine are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    -16.0% -1118.4%
    FCF Margin ROE ROA
    -875.8% -37.6% -24.9%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    GoodWhale recently conducted an analysis of EDITAS MEDICINE‘s wellbeing and have found that it is a high risk investment in terms of financial and business aspects. We looked at their balance sheet, cashflow statement, and financial journal to identify any potential risks that investors should be aware of. From our analysis, we have detected three major risk warnings that could have a significant impact on EDITAS MEDICINE’s potential for success. As a registered user, you can access our comprehensive report on EDITAS MEDICINE. Our report contains detailed information on their financials, business operations, and risk warnings so that you can make the best decision when deciding whether or not to invest in this company. We believe that our analysis can help you make the most informed decisions about your investments. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    In the world of gene-editing, three companies have emerged as leaders in the race to develop CRISPR-based treatments: Editas Medicine Inc, Intellia Therapeutics Inc, and CRISPR Therapeutics AG. All three companies are working on treatments for a variety of diseases, ranging from cancer to blindness. However, only Editas has begun to clinical trials on humans. This gives them a significant advantage over their competitors. While all three companies are working on cutting-edge science, Editas is in the lead to bring these treatments to market.

    – Intellia Therapeutics Inc ($NASDAQ:NTLA)

    Intellia Therapeutics Inc is a genomic editing company. Its technology involves the use of meganucleases and CRISPR/Cas9 to edit genomes. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.

    As of 2022, Intellia Therapeutics Inc has a market cap of 4.19B and a Return on Equity of -43.06%. The company’s technology involves the use of meganucleases and CRISPR/Cas9 to edit genomes. Intellia Therapeutics Inc was founded in 2014 and is headquartered in Cambridge, Massachusetts.

    – CRISPR Therapeutics AG ($NASDAQ:CRSP)

    CRISPR Therapeutics AG is a clinical-stage biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases. Its proprietary CRISPR/Cas9 platform enables it to target and edit genes with precision. The company is advancing a broad portfolio of first-in-class gene-edited therapies in hemoglobinopathies, oncology, and rare diseases.

    – Beam Therapeutics Inc ($NASDAQ:BEAM)

    Beam Therapeutics Inc is a clinical-stage biotechnology company. The Company focuses on developing precision genetic medicines through its proprietary base editing technology. Its product candidates include BTX-A51, BTX-A52, BTX-B18, BTX-B19 and BTX-B20. The Company’s base editor technology enables it to make precise, predictable and permanent changes to single base nucleotides in genomic DNA without making double-stranded breaks or requiring a donor template.


    EDITAS MEDICINE reported lower revenue for the second quarter of FY2023, with total revenue of USD 2.9 million, a 54.6% decrease compared to the same time last year. Despite this, net income improved 24.1%, from -53.4 million to -40.3 million. The stock price reacted positively to the news, moving up the same day.

    For investors, it appears that EDITAS MEDICINE has begun to overcome some of its financial difficulties, and may be poised for further growth in future quarters. Overall, despite the lower revenue, the news appears to indicate a positive outlook for the company.

    Recent Posts

    Leave a Comment